Top Story

Everolimus–exemestane combination failed to significantly extend OS in advanced breast cancer

October 21, 2014

The addition of everolimus to exemestane extended OS in postmenopausal women with HR-positive, HER-2–negative advanced breast cancer, but the difference was not statistically significant, according to results of the BOLERO-2 study.

BOLERO-2 is a randomized phase 3, double blind, international trial.

figure In the Journals

Knowledge of individual risk did not increase colorectal cancer screening adherence

October 20, 2014
Receipt of individualized genetic and environmental risk assessments did not increase colorectal cancer screening rates, even among study participants whose assessments…
FDA News

FDA grants fast track designation to TAS-102 for mCRC

October 20, 2014
The FDA granted fast track designation to an investigational drug combination as a potential treatment for patients with refractory metastatic colorectal cancer, the…
Worth Building

Follow a checklist to help decide what to do with estate life insurance

October 20, 2014
Before recent changes in estate laws, it was common for attorneys, financial planners and insurance agents to recommend purchasing life insurance — commonly called…
More News Headlines »

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »